Machine Could Sequence Human Genome in a Year
A new gene-reading machine is so much faster than existing technology that it could sequence the human genome in a year while it took more than 10 years the first time around.
Biotech Raises More Cash in 2003 But Europe Weak
The global biotechnology industry raised more money by the end of September than in the whole of 2002 but a revival in Europe, which remains weak, could be more than six months away, industry analysts said on Tuesday.
Is That Daylight for ImClone?
The beleaguered drugmaker finally gets some good news with Swiss approval of its cancer-fighting drug Erbitux
Over the Rainbow Yet?
Consolidation slows, valuations grow, and now hope for some IPOs
With the necessary tools at hand, the race is on to build � and market � the first affordable, portable, fully functional DNA analyzer. Is the world ready?
Industry offers proposals to fight growing problem of fake drugs.
BAYER CHEMICALS TO TAKE A SPIN
Split-off of chemicals will shift firm�s focus to life sciences
BIOTECH SCORES BIG THIRD-QUARTER GAINS
Substantial revenue and earnings growth continued unabated for yet another quarter
DRUG EARNINGS RALLY IN THE THIRD QUARTER
Major pharmaceutical firms see improvement in sales and earnings as the year progresses
It Lives for 29 Years?
A lawsuit filed April 11 in the U.S. District Court in Los Angeles has grabbed the attention of the life sciences community. The key parties are three high-profile biotech developers: MedImmune, Genentech and Celltech. MedImmune is challenging the validity and enforceability of an important Genentech patent. Behind that patent, MedImmune charges, is an illegal, anti-competitive agreement that ‘profoundly and fundamentally altered the competitive landscape in the biotechnology industry.’